Testosterone Enanthate 400, often referred to as Enantat 400 or Test E 400 is a high-concentration injectable testosterone ester used in clinical and performance contexts. Known for its extended ...

Xyosted carries a Boxed Warning regarding blood pressure increases that may potentially increase the risk for major adverse cardiovascular events. The Food and Drug Administration (FDA) has approved ...

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Three new testosterone therapies offer innovative drug delivery options for men with hypogonadism ...

Prior to starting Xyosted, the patient's baseline cardiovascular risk should be considered and blood pressure should be adequately controlled. Antares Pharma announced the launch of Xyosted ...

Testosterone regulates many physiological processes, including muscle protein metabolism, some aspects of sexual and cognitive functions, secondary sex characteristics, erythropoiesis, plasma lipids, ...

The US Food and Drug Administration (FDA) has approved testosterone enanthate (Xyosted, Antares Pharma) subcutaneous injection for testosterone replacement therapy in men diagnosed with conditions ...

The US Food and Drug Administration (FDA) has declined to approve a new drug application (NDA) for testosterone enanthate (Xyosted, Antares Pharma) in a proprietary autoinjector and has raised two ...

Men with inadequate testosterone and clinical symptoms of deficiency may have hypogonadism. Here are the signs that should prompt lab study. The diagnosis of hypogonadism demands both symptoms of ...

Please provide your email address to receive an email when new articles are posted on . The estimated male population in their reproductive years is about 52 million in the United States, with the age ...

Testosterone propionate was once a common treatment for men with low testosterone. It’s a synthetic version of the naturally occurring hormone. This solution and other drugs that mimic testosterone ...

TORONTO—Testosterone undecanoate administered every three months is a safe treatment for hypogonadal men, according to a four-year study. Parenteral testosterone undecanoate (TU) was administered to ...